Education
About Us
Working with TipRanks
Follow Us
Cannara Biotech (LOVFF)
OTHER OTC:LOVFF
Total Valuation
Cannara Biotech has a market cap or net worth of $126.70M. The enterprise value is $185.96M.
Market Cap$126.70M
Enterprise Value$185.96M
Share Statistics
Cannara Biotech has 95,782,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding95,782,150
Owned by Insiders48.62%
Owned by Institutions―
Financial Efficiency
Cannara Biotech’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.86%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)10.86%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee232.79K
Profits Per Employee28.36K
Employee Count461
Asset Turnover0.64
Inventory Turnover1.35
Valuation Ratios
The current PE Ratio of Cannara Biotech is 13.8. Cannara Biotech’s PEG ratio is 0.13.
PE Ratio13.8
PS Ratio1.57
PB Ratio1.64
Price to Fair Value1.64
Price to FCF12.31
Price to Operating Cash Flow7.89
PEG Ratio0.13
Income Statement
In the last 12 months, Cannara Biotech had revenue of 107.32M and earned 13.08M in profits. Earnings per share was 0.14.
Revenue107.32M
Gross Profit47.22M
Operating Income22.20M
Pretax Income18.10M
Net Income13.08M
EBITDA28.18M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was 20.77M and capital expenditures -9.76M, giving a free cash flow of 11.01M billion.
Operating Cash Flow20.77M
Free Cash Flow11.01M
Free Cash Flow per Share0.11
Dividends & Yields
Cannara Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change72.30%
50-Day Moving Average1.27
200-Day Moving Average1.19
Relative Strength Index (RSI)44.83
Average Volume (3m)2.46K
Important Dates
Cannara Biotech upcoming earnings date is Apr 29, 2026, Before Open (Confirmed).
Last Earnings DateJan 26, 2026
Next Earnings DateApr 29, 2026
Ex-Dividend Date―
Financial Position
Cannara Biotech as a current ratio of 2.40, with Debt / Equity ratio of 31.34%
Current Ratio2.40
Quick Ratio1.10
Debt to Market Cap0.24
Net Debt to EBITDA0.97
Interest Coverage Ratio5.10
Taxes
In the past 12 months, Cannara Biotech has paid 5.02M in taxes.
Income Tax5.02M
Effective Tax Rate0.28
Enterprise Valuation
Cannara Biotech EV to EBITDA ratio is 6.93, with an EV/FCF ratio of 14.31.
EV to Sales1.82
EV to EBITDA6.93
EV to Free Cash Flow14.31
EV to Operating Cash Flow9.76
Balance Sheet
Cannara Biotech has $16.52M in cash and marketable securities with $34.85M in debt, giving a net cash position of -$18.34M billion.
Cash & Marketable Securities$16.52M
Total Debt$34.85M
Net Cash-$18.34M
Net Cash Per Share-$0.19
Tangible Book Value Per Share$1.09
Margins
Gross margin is 38.59%, with operating margin of 20.68%, and net profit margin of 12.18%.
Gross Margin38.59%
Operating Margin20.68%
Pretax Margin16.86%
Net Profit Margin12.18%
EBITDA Margin26.26%
EBIT Margin20.29%
Analyst Forecast
The average price target for Cannara Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―